Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
暂无分享,去创建一个
David W. Johnson | A. Levin | V. Jha | G. Remuzzi | M. Jardine | V. Perkovic | D. Wheeler | A. Cass | J. Floege | J. Feehally | J. Lv | S. Barbour | Zhi-Hong Liu | D. Cattran | H. Reich | Yangfeng Wu | M. Wong | R. Glassock | R. Agarwal | Minghui Zhao | S. Stepien | L. Billot | Hong Zhang | L. Hooi | M. Hladunewich | K. Rogers | H. Monaghan | M. Woodward | Tak Mao Chan | Kris Rogers | T. Chan | A. Levin
[1] David W. Johnson,et al. Corticosteroid therapy in IgA nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.
[2] C. Fitzner,et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. , 2015, The New England journal of medicine.
[3] K. Nitta,et al. Prognosis in IgA Nephropathy: 30-Year Analysis of 1,012 Patients at a Single Center in Japan , 2014, PloS one.
[4] Mark Haas,et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. , 2017, Kidney international.
[5] A. Levin,et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. , 2013, Kidney international.
[6] J. Floege,et al. Primary glomerulonephritides , 2016, The Lancet.
[7] B. Julian,et al. Current Understanding of the Role of Complement in IgA Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.
[8] A. McGrogan,et al. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] B. Julian,et al. IgA nephropathy. , 2020, The New England journal of medicine.
[10] H. Reich,et al. IgA Nephropathy: Core Curriculum 2021. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] B. Rovin,et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.
[12] David W. Johnson,et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial , 2017, JAMA.
[13] B. Rovin,et al. Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy , 2020, Kidney international reports.
[14] J. Barratt,et al. New strategies and perspectives on managing IgA nephropathy , 2019, Clinical and Experimental Nephrology.
[15] B. Julian,et al. The pathophysiology of IgA nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.
[16] David W. Johnson,et al. The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics , 2021, American Journal of Nephrology.
[17] F. Locatelli,et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial , 2017, The Lancet.
[18] C. Wanner,et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. , 2020, Kidney international.
[19] J. Craig,et al. Immunosuppressive agents for treating IgA nephropathy. , 2003, The Cochrane database of systematic reviews.